TREATMENT OF HELICOBACTER PYLORI INFECTION AND IMPACT OF ITS ERADICATION IN PEPTIC ULCER DISEASE

Abstract

Introduction: Helicobacter pylori (H. pylori) continues to be a major worldwide health issue, impacting around 50% of the global population, despite the progress made in the field of medical science. H. pylori infection consistently causes chronic active gastritis and can culminate in serious gastroduodenal conditions, such as gastric mucosa-associated lymphoid tissue (MALT) lymphoma, noncardiac gastric cancer, and peptic ulcer disease.

Methodology: The study was conducted between July 2023 to December 2023 at a tertiary care hospital in Pakistan. A data collection form was used to collect patients ‘data which included demographic details, primary diagnosis, past medical history, past medication details, current medication in the hospital, ulcer associated symptoms and factors that could exacerbate the condition, and the prescription at hospital.

Results: A total of 84 participants were included in the study among whom 36 were males. 10.7% patients were presented with a wide spectrum of symptoms presenting complications. Hypertension and diabetes mellitus were common comorbid conditions, and the BMI mean was 28.71±2.43. The patients were observed over a period of six months and the relief of symptoms was noted. The severity of symptoms reduced in 63 (75%), the Quadruple Regimen was more effective for the complicated cases

Conclusion: The implementation of eradication therapy not only promotes the healing of ulcers and decreases the likelihood of them reoccurring, but also diminishes the long-term probability of developing gastric cancer. This highlights the importance of ongoing study and advancement in ways for managing H. pylori.